Mouse igg1kappa isotype control pe

Manufactured by BioLegend

Sourced in United States

Mouse IgG1kappa isotype control-PE is a laboratory reagent used to establish background fluorescence levels in flow cytometry experiments. It serves as a control to differentiate specific from non-specific antibody binding.

Automatically generated - may contain errors

Lab products found in correlation

Red blood cell lysis buffer, by BioLegend (2 mentions) Mouse igg1kappa isotype control apc clone mopc 21, by BioLegend (2 mentions) Novocyte, by Agilent Technologies (2 mentions) Pe anti human cd25, by BioLegend (1 mentions) Apc anti human cd69, by BioLegend (1 mentions) Apc anti human cd107a, by BioLegend (1 mentions) Pe anti human cd8, by BioLegend (1 mentions) Anti human cd3 apc, by BioLegend (1 mentions) Lsrfortessa, by BD (1 mentions) C6 flow cytometer, by BD (1 mentions) True nuclear transcription factor buffer set, by BioLegend (1 mentions) Fortessa cytometer, by BD (1 mentions)

3 protocols using mouse igg1kappa isotype control pe

Comprehensive Flow Cytometry Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols

All samples were analyzed using a NovoCyteTM (ACEA Biosciences), LSR Fortessa, or C6 flow cytometer (BD Biosciences), and data were analyzed using FlowJo software (FlowJo, LLC, Ashland, OR, USA). The antibodies used included anti-MSLN-biotin (clone MB), Streptavidin-APC, anti-human CCR7-APC (clone 3D12), anti-human CD62L-PE (clone DREG-56), anti-human CD45RA-APC (clone HI100), anti-human CD45RO-PE (clone UCHL1), anti-human TIM3-PE (clone F38-2E2), anti-human LAG3-PerCP/Cy5.5 (clone 11C3C65), anti-human PD-1-APC (clone NAT105), anti-human CD27-PE (clone M-T271), anti-human CD28-APC (clone CD28.2), anti-human CD25-PE (clone BC96), anti-human CD69-APC (clone FN50), anti-human CD107a-APC (clone H4A3), anti-human CD3-APC (clone UCHT1), anti-human CD4-PerCP/Cy5.5 (clone OKT4), anti-human CD8-PE (clone OKT8), mouse IgG2a isotype control-APC (clone RMG2a-62), mouse IgG1kappa isotype control-PE, mouse IgG1kappa isotype control-PErCP/Cy5.5, and mouse IgG1kappa isotype control-APC (clone MOPC-21) (Biolegend, San Diego, CA, USA). All FACS-related staining procedures were performed on ice for 30 min, and cells were then washed with PBS containing 1% FBS before cytometry analysis. PB, spleen (SP), and tumor samples from mouse xenografts were treated with red blood cell lysis buffer (Biolegend), and the cells were stained with the corresponding antibodies.

Lv J., Zhao R., Wu D., Zheng D., Wu Z., Shi J., Wei X., Wu Q., Long Y., Lin S., Wang S., Wang Z., Li Y., Chen Y., He Q., Chen S., Yao H., Liu Z., Tang Z., Yao Y., Pei D., Liu P., Zhang X., Zhang Z., Cui S., Chen R, & Li P. (2019). Mesothelin is a target of chimeric antigen receptor T cells for treating gastric cancer. Journal of Hematology & Oncology, 12, 18.

+ Open protocol

+ Expand

Comprehensive Immune Profiling by Flow Cytometry

Check if the same lab product or an alternative is used in the 5 most similar protocols

Flow cytometry was performed on a Fortessa cytometer (BD Biosciences, San Jose, CA), and data were analyzed using FlowJo software (FlowJo, LLC, Ashland, OR, USA). The antibodies used, including anti-human CD3-APC (clone UCHT1), anti-human CD4-APC (clone OKT4), anti-human CD8-PE (clone OKT8), anti-human CD279 (PD-1)-APC (clone eBioJ105), anti-human NKG2D-APC (clone 1D11), anti-human CD25-PE (clone BC96), anti-human CD69-APC (clone FN50), anti-human CD107a-APC (clone H4A3), anti-human T-bet-percpcy5.5(Clone 4B10), mouse IgG1kappa isotype control-PE and mouse IgG1kappa isotype control-APC (clone MOPC-21), were purchased from Biolegend, San Diego, CA, USA. All FACS-related staining was performed on ice for 30 minutes, and cells were then washed with PBS containing 1% FBS before cytometry analysis. Intracellular staining of T-bet was achieved with True-Nuclear™ Transcription Factor Buffer Set (Biolegend, San Diego, CA, USA). Peripheral blood (PB), spleen (SP) and tumor samples from mouse xenografts were treated with red blood cell lysis buffer (Biolegend), and the cells were stained with the corresponding antibodies.

Zhao R., Cheng L., Jiang Z., Wei X., Li B., Wu Q., Wang S., Lin S., Long Y., Zhang X., Wu Y., Du X., Pei D., Liu P., Li Y., Cui S., Yao Y, & Li P. (2018). DNAX-activating protein 10 co-stimulation enhances the anti-tumor efficacy of chimeric antigen receptor T cells. Oncoimmunology, 8(1), e1509173.

+ Open protocol

+ Expand

Multiparametric Analysis of Immune Cell Subsets

Check if the same lab product or an alternative is used in the 5 most similar protocols

Cells were harvested and suspended in 50 μl 1 x PBS and primary labeled antibodies were added subsequently. The antibodies used included anti-human PSCA-APC antibody (clone 75) from Santa Cruz Biotechnology (Dallas, TX, USA), anti-human CCR7-APC (clone 3D12), anti-human CD62L-PE (clone DREG-56), anti-human CD45RA-APC (clone HI100), anti-human CD45RO-PE (clone UCHL1), anti-human CD27-PE (clone M-T271), anti-human CD25-PE (clone BC96), anti-human CD69-APC (clone FN50), anti-human CD107a-APC (clone H4A3), anti-human CD3-APC (clone UCHT1), anti-human CD4-PerCP/Cy5.5 (clone OKT4), anti-human CD8-PE (clone OKT8), mouse IgG2a isotype control-APC (clone RMG2a-62), and mouse IgG1 kappa isotype control-PE (Biolegend, San Diego, CA, USA). The samples were incubated at 4 °C for 30 min before analyzed by NovoCyteTM (ACEA Biosciences), and data were analyzed using FlowJo software (FlowJo, LLC, Ashland, OR, USA).

Wu D., Lv J., Zhao R., Wu Z., Zheng D., Shi J., Lin S., Wang S., Wu Q., Long Y., Li P, & Yao Y. (2020). PSCA is a target of chimeric antigen receptor T cells in gastric cancer. Biomarker Research, 8, 3.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!